Introduction
Hysterectomy (from Greek ὑ έρα hystera "womb" and εκ ομία ektomia "a cutting out of") is the surgical removal of the uterus. Hysterectomy may be total (removing the body, fundus, and cervix of the uterus; often called "complete") or partial (removal of the uterine body while leaving the cervix intact; also called "supracervical"). It is the most commonly performed gynaecological surgical procedure although the incidence of hysterectomy varies widely across the world. 1 This is the case even when one considers only developed countries with comparable resources. In 2003, over 600,000 hysterectomies were performed in the United States alone, of which over 90% were performed for benign conditions. 2 In the USA a woman's life-time risk of hysterectomy is 25%, which compares to a much lower risk of 10.4% in Denmark. 3 In England and Wales the hysterectomy rate in NHS hospitals is estimated at 28 per 10,000 women per annum. 4 Even within each country, there are large regional variations. 5 Such rates being highest in the industrialized world has led to the major controversy that hysterectomies are being largely performed for unwarranted and unnecessary reasons.
Oophorectomy is frequently done together with hysterectomy to decrease the risk of ovarian cancer. However, recent studies have shown that prophylactic oophorectomy without an urgent medical indication has serious consequences. 6 Apart from the current occurrence of estrogen deficiency symptoms, women who are oophorectomized, particularly at an early age experience an increased risk of ischaemic heart disease as well as death from cardiovascular disease. Oophorectomy also leads to early loss of bone and an increased risk of osteoporotic fracture and may also be linked to impaired cognitive function. The impact on psychological health could also be substantial leading to long lasting anxiety, depression, loss of self-esteem and well-being and may also indirectly or directly give rise to problems of sexual function. This effect is not limited to pre-menopausal women; even women who have already entered menopause were shown to have experienced a decrease in long-term survivability post-oophorectomy. 7 The LNG-IUS
Alternatives to hysterectomy in women with bleeding disorders and other gynaecological conditions
A Non-steroidal anti-inflammatory drugs Mefenamic acid, and the antifibrinolytic agent tranexamic acid are effective treatments and are considered first-line treatment for menorrhagia. 22 The efficacy of these treatments has been demonstrated in several randomized trials and reported in systematic reviews. 23, 24 Tranexamic acid reduces menstrual loss by about 50% and mefenamic acid by a third. Both drugs also relieve menstrual cramps.
B Systemically administered hormones
Cyclical progestogens given during the luteal phase of the cycle are ineffective, but are effective when given continuously for 21 days. 25 Side effects such as breakthrough bleeding, breast tenderness, weight gain, alteration in libido and depression reduce compliance. The additional contraceptive effect limits their use in women who wish to conceive. Where contraception is desired, the combined oral contraceptive pill appears to be a better choice for the treatment of menorrhagia. The hormones work by inhibiting the growth and development of the endometrium, thus significantly reducing blood loss.
C Locally administered hormones
The main focus of this section will be on the local administration of levonorgestrel (LNG) using an intrauterine drug delivery system (IUS) as LNG is a potent progestogen with many advantages. 26 The progesterone-releasing intrauterine device (IUD) will not be discussed as the Progestasert ® IUD is not commercialized anymore. The natural hormone is much weaker than LNG and, therefore, less suitable for the treatment purposes described in this paper.
Our research group has been involved in the clinical development of frameless and framed LNG-releasing intrauterine systems since 1997. Another chapter in this book focuses on the effect of these systems on menstrual blood loss in women with and without heavy menstrual bleeding or menorrhagia. This section will mainly focus on the differences between these novel devices compared to the Mirena ® LNG-IUS (BayerSchering AG, Berlin, Germany). In addition, the use of the LNG-IUS will be discussed for the treatment of precancerous lesions of the endometrium, including early endometrial cancer of the endometrium, conditions that usually are treated by hysterectomy.
In order to be successful as a method for intrauterine treatment, the prerequisite is that the following conditions are met. The method should:
1. be easy and safe to apply 2. be well-tolerated and fit in cavities of every size and shape 3. be well retained 4. release a sufficient amount of active substance per day 5. preferably release a high dosage during the first few weeks to establish fast and profound suppression of the endometrium 6. be long-acting 7. have few side effects and 8. be easy to remove a. Comparison between Femilis ® LNG-IUS and Mirena ® LNG-IUS Figure 1 depicts both intrauterine systems. The design of Femilis ® is slimmer with shorter crossarms and thinner stem than Mirena ® . Both release a similar amount of LNG (20 µg/day) except for the first weeks whereby comparative in vitro release studies showed that the release rate of Femilis ® is approximately 2 to 3 times higher. Femilis ® and Mirena ® have a duration of action of at least 5 years. The difference in design is important as it has a bearing on the easiness and safety of the insertion procedure as well as on the acceptability and retention of the LNG-IUS.
As Femilis ® is significantly smaller that Mirena ® , it is suitable for parous as well as nulliparous women. Women with narrow, but not too narrow, uterine cavities tolerate the LNG-IUS. Figure 3 shows the blister package of Femilis ® with uterine sound. Uterine cavities differ considerably in size and shape, and the uterus is subject to changes in size and volume during the menstrual cycle. 27, 28 These changes are most pronounced at the time of menses. These individual variations in size and shape of the human uterus are probably greater than variations of the human foot (H.M. Hasson). Research has shown that if the width of the uterine cavity is too small, side effects and complications are likely to occur. The crossarms of standard T-shaped IUDs are frequently too long for a large number of uterine cavities, as the average transverse diameter of the uterine cavity in the majority of women is smaller than the span of the crossarms of the IUD. The average transverse IUDs with respect to their indication for sonography and found that the proportion of patients whose principal indication for sonography was bleeding, pain or bleeding and pain were significantly greater in those with an abnormally located IUD, including imbedded IUDs, compared with those whose IUD was not located abnormally on 3-D sonography. 29, 30 It should be noted that standard 2-D sonography is not able to detect many abnormally located IUDs particularly with regard to abnormal location of the sidearms of the IUD. Accurate location of the sidearms is only possible by hysteroscopy and with 3-D coronal sonography, as shown in Figure 6 . Due to the shorter crossarms of the Femilis ® LNG-IUS it has been demonstrated in clinical trials that the IUS fits better in uterine cavities with small transverse dimensions. This indicates that side effects (e.g., pain, bleeding and expulsion) due to incompatibility can be avoided by reducing the length of the crossarms. IUDs that do not fit well contribute to early discontinuation. 31 In addition, insertion of the Femilis ® IUS is straightforward. Following uterine sounding, the IUS is simply pushed in the uterine cavity, up to the fundal wall. The ease and safety of this insertion technique was demonstrated in a multicenter clinical trial. 32, 33 b. Use of the LNG-IUS in women with precancerous or early cancer of the endometrium
The use of the LNG-IUS as an alternative to hysterectomy for treatment of heavy menstrual bleeding was covered in another chapter in this book. Other uterine pathologies such as precancerous changes of the endometrium and even early endometrial cancer of the uterus can effectively be treated by the LNG-IUS. Our group evaluated the effect on endometrial non-atypical and atypical hyperplasia in 20 women. The aim of the study was to evaluate the long-term cure (remission) rate. All women in this small series developed a normal endometrium, except one asymptomatic woman with atypical hyperplasia who still had focal residual non-atypical hyperplasia at 3 years follow-up in the presence of a thin (<4 mm) endometrium. This patient is being followed-up on a regular basis. It was concluded that continuous intrauterine delivery of LNG appears to be a promising alternative to hysterectomy for the treatment of endometrial hyperplasia and could enhance the success rate when compared with other routes of progestogen administration as well as intrauterine progesterone delivery. 34 As many women with atypical hyperplasia harbour cancer cell, patients should be followed-up long-term and the endometrium should continuously kept suppressed with a LNG-IUS.
Two cases of early, respectively well-and moderately differentiated endometrial carcinoma were also effectively treated with the LNG-IUS. Below is the summarized report of one of these patients. The patient presented with minimal postmenopausal bleeding. An outpatient endometrial pipelle biopsy was performed which revealed a moderately differentiated adenocarcinoma ( Figure 7 ) with minimal myometrial invasion (Clinical FIGO stage I). 35 An LNG-IUS (Femilis ® ) was inserted and advice was given to conduct a repeat biopsy within the next 3 to 6 months. Spotting continued for several weeks and then stopped. As the patient was completely free of symptoms 6 months after insertion of the LNG-IUS, a pelvic transvaginal ultrasound was performed, including a 3-D ultrasound. The uterus appeared completely normal, and there was no evidence of any pathology. The endometrium showed normal thickness, and there was no evidence of any endometrial abnormality or myometrial invasion. The LNG-IUS was identified in situ, as expected. Six months later, in order to ascertain complete remission, it was decided to remove the LNG-IUS and to perform a full D&C. The uterine sound length was 6 cm. The whole cavity was explored, and very scant tissue was removed. Histological examination of the specimen revealed a secretory www.intechopen.com Eighteen insertions were performed in women between 16 and 52 years of age. Eight women were categorized as having primary and 10 having secondary dysmenorrhea. Twelve women complained of heavy bleeding. Two women had significant fibroids and three were suspected to have adenomyosis. All women, except one with significant fibroids, reported much reduced pain, no pain at all, or strongly reduced bleeding, which started as soon as one month after insertion of the frameless LNG-IUS. The results of this small study suggest that the LNG-IUS could be an effective method in women with primary or secondary dysmenorrhea, associated or not with excessive menstrual bleeding, and avoid surgery in many of them as both bleeding and pain are effectively treated with the LNG-IUS. An additional advantage is that the LNG-IUS is a potent contraceptive as well. The absence of a frame is particularly advantageous in these cases as it does not elicit uterine contractions.
Endometriosis affects almost 10-20% of women of reproductive age, while 70-90% of women with chronic pelvic pain (CPP), dysmenorrhea, dyspareunia, infertility and menstrual disturbances also have endometriosis, a disease that impairs patients' quality of life. 36 Many therapies are proposed. These include nonsteroidal anti-inflammatory drugs, antiestrogens, progestogens such as depot medroxyprogesterone acetate (DMPA), GnRH analogues to induce pseudo-menopause, androgen derivatives (danazol) and continuous combined oral contraceptives (COC) to induce pseudo-pregnancy. Medical treatments are based on the reduction of lesions or on ovarian estrogen suppression; however, adherence and long-term therapy continue to represent a challenge in the management of endometriosis. Because of the profound hypoestrogenism provoked by some of these drugs, bone mineral density is the principal concern that limits their use to 6 months, although longer treatment with add-back hormone therapy is possible. GnRH-a is also expensive and not readily available to women worldwide, especially in developing countries.
One of the options to treat these conditions, and alleviate the pain complaints, is the levonorgestrel-releasing intrauterine system. Bahamondes et al. recently reviewed the literature regarding the use of LNG-IUS (Mirena ® ) in women with endometriosis, adenomyosis, cyclic pelvic pain and dysmenorrhea. 37 They found that all studies reported an improvement in pelvic pain and dysmenorrhea, and a reduction in menstrual bleeding. One study found an improvement in the staging of the disease at 6 months of use, and the studies that evaluated the use of LNG-IUS in women with adenomyosis reported a reduction in uterine volume. Furthermore, the only study in which women were followed up for 3 years after insertion found improvement in pelvic pain at 12 months of use, but no improvement after that period. They concluded that the use of LNG-IUS is an alternative for the medical treatment of women suffering from endometriosis, adenomyosis, chronic pelvic pain or dysmenorrhea, but that experience is limited and long-term studies are necessary to reach definitive conclusions. Other authors came to the same conclusion. 38 However, for women who do not wish to become pregnant, this device offers the possibility of at least 5 years of treatment following one single intervention. It is to be expected that many of these women, without further fertility, could avoid surgical treatment which would be viewed as an enormous benefit for those concerned.
Given the above scientific evidence, it should be concluded that the LNG-IUS is effective for the treatment of the most frequently occurring gynaecological conditions for which gynaecologists are consulted. The use of local medical treatment has many advantages and should, therefore, be considered as the first line treatment before a surgical intervention. 39, 40 In a randomized trial comparing the LNG-IUS with hysterectomy, 42% in the LNG-IUS group subsequently underwent hysterectomy, and, thus, surgery and the associated risks www.intechopen.com with surgery were avoided in 58% of the women. The number of hysterectomies for menorrhagia in England has fallen substantially to just over one third (36%) of the number of a decade ago ( Figure 9 ). 41 This trend can be explained by an increase in medical treatment as well as by the more widespread use of endometrial resection or ablation. 
D Endometrial ablative techniques
In recent years various surgical techniques have been developed to ablate the endometrium. An excellent review on these techniques was recently published. 10 The reader is therefore referred to this paper. It suffices to make some observations and conclusions.
The endometrial ablative techniques can be divided into two broad groups: the firstgeneration hysteroscopic endometrial ablation (HEA) procedures performed under direct vision, and the second-generation non-hysteroscopic endometrial ablation (NHEA) procedures which are largely 'blind'. These techniques are mainly used to treat women with excessive menstrual bleeding. They are summarized in Table 1 . The techniques are simpler and quicker to perform than hysteroscopic methods, while satisfaction rates and reduction in menstrual blood loss are high (up to 90%) Women choosing one of these options need to be aware that they are likely to continue to experience some degree of menstrual bleeding and that further surgery may be necessary for persistent heavy bleeding
The data on the safety of all the second generation techniques are as yet incomplete, but all systems appear to be associated with minimal complication rates 
GnRH analogues in the management of uterine fibroids
Advantages Disadvantages -GnRH analogues prior to either hysterectomy or myomectomy has shown that uterine volume and size, as well as fibroid volume, were all reduced, as were pelvic symptoms -Hysterectomy is rendered easier, with reduced operating time, and a greater proportion of hysterectomy patients were able to have a vaginal rather than an abdominal procedure -Blood loss and rate of vertical incision were reduced for both myomectomy and hysterectomy -Duration of hospital stay was reduced -Disadvantages of GnRH analogues include cost, menopausal symptoms (but can be prevented by 'add-back' HRT) and, with prolonged therapy, bone demineralization -Some believe that benefits do not justify the costs -GnRH analogues render surgical planes less distinct, perhaps due to softening of the fibroids, which makes enucleation more difficult -Their use as primary therapy in younger women is questionable as fibroids re-grow to their original size within a few months of discontinuation of treatment
Uterine artery embolization (UAE)
Advantages Disadvantages -Clinical success rates are good with good fibroid shrinkage rates (10-70%) and symptom improvement (70-94%) -UAE is now widely practiced in Western Europe and North America, and the National Institute for Clinical Excellence (NICE) in the UK has decreed that it can be routinely offered as a primary treatment for uterine fibroids, although it is recommended that all procedures are registered -However, the fact remains that UAE has never been compared with conventional treatments in a prospective randomized controlled trial (RCT), as either a pilot or a full study -There is also a lack of long-term data -Complications secondary to arterial puncture, contrast injection, arterial catheterization and non-target-organ embolization are intrinsic to all embolization procedures, but are uncommon, and further minimized by operator experience and good technique -Chronic discharge is a frequent complication, affecting up to 7% of patients -Infections are also more common with larger fibroids -Fibroid extrusion occurs in about 10% of cases.
Larger ones may necessitate a surgical procedure for removal, especially if impacted at the cervix -Clinical features of the so-called postembolization syndrome include a flu-like illness, high temperature, high white cell count and a feeling of malaise, and may be due to release of cytokines and toxins from the ischaemic tissue. This might be difficult to differentiate from sepsis Table 2 . Summarizes these new approaches, their advantages and disadvantages (adapted from Banu et al. 10 ).
A Cochrane review concluded that while short-term follow-up studies might indicate an advantage for endometrial ablation, longer-term studies show a narrowing of the gap, and hysterectomy appears to have consistently higher rates of satisfaction and better healthrelated quality-of-life outcomes. 44 A study conducted by Maia et al. is also worth mentioning in this respect. 45 They investigated 106 women with HMB. After endometrial resection, the women were randomized into two groups, 53 women in each. Women in the treatment group were fitted with Mirena ® . In this group, amenorrhoea was achieved in 72% of cases after 3 months, in 89% after 6 months and in 100% after 1 year. In the resection-only group, the corresponding numbers were 19%, 17% and 9%, and in this group, 19% of the women underwent a second resection.
A second study by Maia et al. (CEPARH, Brazil) was recently reported at the World Congress on the Menopause (Abstract Book p. 74). Ninety-two perimenopausal women with menorrhagia, dysmenorrhea and premenstrual syndrome (PMS) were enrolled in this study. Sixty-two patients had adenomyosis and the remaining 30 had submucous and intramural myomas. The use of the LNG-IUS (Mirena ® ) following endometrial resection significantly increased amenorrhoea rates. The rate was 98% in the fifth year. Complete resolution of dysmenorrhea and PMS was reported by over 90% of patients. In historical controls submitted to endometrial resection, the amenorrhoea rate was only 20% with a failure rate of 40%. This study also showed an inhibition of the expression of aromatase in the ectopic glands in the myometrium of patients with adenomyosis, thereby contributing towards www.intechopen.com interrupting the progression of the disease. This may explain why the rates of amenorrhoea are far superior to those achieved with endometrial resection alone. It was concluded that endometrial resection with LNG-IUS is a viable alternative to hysterectomy in perimenopausal women.
E. Alternative therapies for the management of fibromyomas
Uterine myoma (leiomyoma, fibromyoma, fibroid) is a very common disease. They are more common in certain ethnic populations, especially the Afro-Caribbean. 46 Leiomyomas occur with an incidence of up to 77%. 47 Fibroids can cause menorrhagia, pelvic pain/discomfort, and bladder and bowel compression symptoms. They are often asymptomatic but some 25-50% of women will experience symptoms such as menorrhagia and pelvic discomfort. About 5% of the fibroids are intracavitary and submucosal and are most difficult to treat. 48, 49 Hysterectomy is still the most commonly used procedure although medical treatments are preferable. 50, 51 Uterine fibroids are responsible for 30% of hysterectomies. Notwithstanding the success of radical surgery, it is not always desirable particularly in the younger woman desiring fertility. Also psychological factors play a role as the uterus has been regarded as a sexual organ, a source of energy and vitality, and a maintainer of youth and attractiveness. Many women, therefore, might wish to avoid a hysterectomy, even when their families are complete.
Recently, new conservative treatment options have been developed such as the treatment with GnRH analogs and the levonorgestrel-releasing intrauterine system (LNG-IUS). 52, 53 GnRH analogs, however, are only temporarily indicated before surgical intervention.
Conclusion
Because of its multiple health benefits, the LNG-IUS is likely to continue to conquer the worldwide markets to treat frequent gynaecological conditions and simultaneously provide contraception when needed. In addition, The LNG-IUS may also offer major benefits for the prevention of uterine pathologies and conditions, including endometrial polyps, endometrial hyperplasia, endometrial carcinoma in association or not with tamoxifen treatment of breast cancer, peri-menopausal menstrual disturbances, post-menopausal endometrial hyperplasia with hormone replacement therapy, endometrial hyperplasia and uterine myomas, endometriosis, adenomyosis, acute pelvic inflammatory disease and infertility. 27 Just as we are very conscious about the health benefits of estrogens in the prevention of osteoporotic fractures, the LNG-IUS and other hormone-releasing systems will be used mostly for the prevention of benign diseases in gynaecology. However, successful treatment of precancerous lesions and early cancer of the endometrium are within reach of the LNG-IUS.
The challenge also remains to promote novel LNG-IUSs who are easy to apply and are designed to fit in uterine cavities with different size and shape to improve tolerance and maximize continued use. Furthermore, new conservative approaches and minimally invasive techniques should be explored. Progesterone antagonists and progesterone receptor modulators may have a major role in the future to treat conditions such as fibroids and endometriosis conservatively. Endometriosis accounts for approximately 20% of the hysterectomies currently performed. There is no doubt that these new approaches will help reduce the number of hysterectomies further. However, hysterectomy will always remain the first choice for infiltrative cancer of the uterus and for most forms of pelvic relaxation although vaginal pessaries are increasingly used in older women. Currently, utero-vaginal prolapse is the indication for 15% of hysterectomies.
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